Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 117Stomach Neoplasms 20HER2-positive Breast Cancer 14Neoplasm Metastasis 13Neoplasms 12Colorectal Neoplasms 11Esophageal Neoplasms 9Triple Negative Breast Neoplasms 5Lung Neoplasms 5Colonic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Brain Neoplasms 5Rectal Neoplasms 4Ovarian Neoplasms 4Meningeal Neoplasms 4Endometrial Neoplasms 4Biliary Tract Neoplasms 4Adenocarcinoma Of Esophagus 4Uterine Cervical Neoplasms 3Salivary Gland Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Multiple Myeloma 3Meningeal Carcinomatosis 3Lymphoma, Non-Hodgkin 3Inflammatory Breast Neoplasms 3Hematologic Neoplasms 3Gallbladder Neoplasms 3Breast Diseases 3Anatomic Stage I Breast Cancer AJCC v8 3

Interventions

tucatinib 1pertuzumab 1atezolizumab 1Trastuzumab 1Fulvestrant 1Alpelisib 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Metastatic Breast Cancer × Trastuzumab × 1 year × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡